Ardelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference

Rhea-AI Summary

Ardelyx, Inc. (Nasdaq: ARDX) announced that CEO Mike Raab will participate in a virtual fireside chat at the 2022 Wedbush PacGrow Healthcare Conference. The chat is scheduled for August 9, 2022, at 4:40 p.m. ET. Interested parties can access the live webcast through the Investor section of the Ardelyx website, with a replay available for 30 days post-conference. Ardelyx focuses on developing innovative medicines to address significant medical needs, including their approved product IBSRELA and products in development for conditions like CKD and hyperkalemia.

WALTHAM, Mass., Aug. 2, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a virtual fireside chat at the 2022 Wedbush PacGrow Healthcare Conference. The fireside chat will take place on Tuesday, August 9, 2022, at 4:40 p.m. ET.  

To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available on the Ardelyx website for 30 days following the conference.

About Ardelyx, Inc.

Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx's first approved product, IBSRELA^® (tenapanor) is available in the United States. Ardelyx is developing XPHOZAH^® (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials. Ardelyx has a Phase 2 potassium secretagogue program, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-2022-wedbush-pacgrow-healthcare-conference-301597710.html

SOURCE Ardelyx

FAQ

When will Ardelyx participate in the 2022 Wedbush PacGrow Healthcare Conference?

Ardelyx will participate on August 9, 2022, at 4:40 p.m. ET.

Who is the CEO of Ardelyx that will speak at the conference?

Mike Raab is the CEO of Ardelyx who will be speaking at the conference.

Where can I watch the Ardelyx presentation from the conference?

The presentation can be accessed on the Investor section of the Ardelyx website.

Is there a replay available for the Ardelyx conference presentation?

Yes, a replay of the webcast will be available for 30 days following the conference.

What is the main focus of Ardelyx as a biopharmaceutical company?

Ardelyx focuses on discovering and developing innovative medicines to meet significant unmet medical needs.